Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2017

View Archived Issues

Brickell Biotech reports results of confirmatory phase IIb study of sofpironium bromide

FDA orphan drug status granted to Synlogic's SYNB-1618

FDA awards orphan drug status to Zealand Pharma's glepaglutide

Momelotinib does not appear to add to erlotinib benefit in NSCLC trial

Catalyst Biosciences and Mosaic Biosciences to develop anti-C3 protease compounds

New candidate prodrug TransCon CNP for treating achondroplasia shows promise

Novel PET tracer 68Ga-NOTA-3PTATE-RGD shows promise for imaging lung cancer, neuroendocrine tumors

Alector and AbbVie enter global collaboration to advance novel immune-neurology candidates

Pain Therapeutics completes phase I study of Alzheimer's candidate

Imprimis Pharmaceuticals launches subsidiary

Safety and immunological data presented for TG-1050 for HBV infection

Minneamrita commences phase I testing of oral minnelide in advanced cancer

Novartis reflects on key milestones of third quarter 2017

Bispecific antibody ALG.APV-527 targets tumor antigen 5T4

MJFF and Tau Consortium fund development of novel PET imaging tracers for neurodegenerative diseases

RespiVert and Topivert Pharma patent kinase inhibitors

Pfizer's glasdegib given orphan drug designation for MDS

Ruzasvir/uprifosbuvir combination highly effective in genotypes 1, 2 and 4 HCV infection

Pulmocide divulges novel RSV fusion inhibitors

Alzheon's ALZ-801 awarded fast track designation from FDA

Collaboration to support Amylyx Pharmaceuticals's phase II study of AMX-0035

Immunocore presents constructs for treating HIV infection and AIDS

FDA grants fast track designation to MIV-711 for treatment of osteoarthritis

TVGV-HB vaccine shows promise in HBV mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...